about
Intradermal electroporation of naked replicon RNA elicits strong immune responsesReversible Acid-Induced Inactivation of the Membrane Fusion Protein of Semliki Forest VirusThe 6-kilodalton membrane protein of Semliki Forest virus is involved in the budding processRIG-I-mediated antiviral responses to single-stranded RNA bearing 5'-phosphatesLong peptides induce polyfunctional T cells against conserved regions of HIV-1 with superior breadth to single-gene vaccines in macaques.MyD88 expression is required for efficient cross-presentation of viral antigens from infected cells.Budding of enveloped viruses from the plasma membrane.De-novo transcriptome sequencing of a normalized cDNA pool from influenza infected ferrets.Non-viral amplification systems for gene transfer: vectors based on alphaviruses.Generation of cytotoxic and humoral immune responses by nonreplicative recombinant Semliki Forest virus.Role of innate signalling pathways in the immunogenicity of alphaviral replicon-based vaccinesKinetic and phenotypic analysis of CD8+ T cell responses after priming with alphavirus replicons and homologous or heterologous booster immunizationsHumoral responses against coimmunized protein antigen but not against alphavirus-encoded antigens require alpha/beta interferon signalingAlphavirus replicon DNA expressing HIV antigens is an excellent prime for boosting with recombinant modified vaccinia Ankara (MVA) or with HIV gp140 protein antigen.A 6K-deletion variant of salmonid alphavirus is non-viable but can be rescued through RNA recombination.An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses.Viral vectors for malaria vaccine development.A novel poxvirus-based vaccine, MVA-CHIKV, is highly immunogenic and protects mice against chikungunya infection.DNA immunization followed by a viral vector booster in a Chlamydia pneumoniae mouse model.Self-replicating alphavirus RNA vaccines.Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02).Modification of a salmonid alphavirus replicon vector for enhanced expression of heterologous antigens.Two-helper RNA system for production of recombinant Semliki forest virus particles.Comparative prime-boost vaccinations using Semliki Forest virus, adenovirus, and ALVAC vectors demonstrate differences in the generation of a protective central memory CTL response against the P815 tumor.Efficient expansion of HIV-1-specific T cell responses by homologous immunization with recombinant Semliki Forest virus particles.Semliki Forest virus produced in the absence of the 6K protein has an altered spike structure as revealed by decreased membrane fusion capacity.Delivery and expression of heterologous genes in mammalian cells using self-replicating alphavirus vectors.Live viral vectors: Semliki Forest virus.Immunotherapy with recombinant SFV-replicons expressing the P815A tumor antigen or IL-12 induces tumor regression.Recombinant Semliki Forest virus vaccine vectors: the route of injection determines the localization of vector RNA and subsequent T cell response.Enhancing immune responses using suicidal DNA vaccines.Alphavirus expression vectors and their use as recombinant vaccines: a minireview.Recombinant Semliki Forest virus particles encoding the prME or NS1 proteins of louping ill virus protect mice from lethal challenge.Modulation of vaccine-induced immune responses to hepatitis C virus in rhesus macaques by altering priming before adenovirus boosting.Use of conventional or replicating nucleic acid-based vaccines and recombinant Semliki forest virus-derived particles for the induction of immune responses against hepatitis C virus core and E2 antigens.Low dose and gene gun immunization with a hepatitis C virus nonstructural (NS) 3 DNA-based vaccine containing NS4A inhibit NS3/4A-expressing tumors in vivo.Outcome of immunization of cynomolgus monkeys with recombinant Semliki Forest virus encoding human immunodeficiency virus type 1 envelope protein and challenge with a high dose of SHIV-4 virus.Toll-like receptor 3 promotes cross-priming to virus-infected cells.Vaccine protection from CD4+ T-cell loss caused by simian immunodeficiency virus (SIV) mac251 is afforded by sequential immunization with three unrelated vaccine vectors encoding multiple SIV antigens.Protective efficacy of a multicomponent vector vaccine in cynomolgus monkeys after intrarectal simian immunodeficiency virus challenge.
P50
Q27310340-AF1DA45F-5B33-4B45-8B06-3BA48C6CB256Q27469816-017FDF4F-F13D-4A33-ACC4-88935820712AQ27478445-3AB65C53-CE0A-4765-9590-F7AA35612B14Q27861007-9733D0AD-896C-4D2C-9CCE-7EA71C2FC85DQ33578049-7A236F8E-D1E6-45F1-8935-05FF494A3F32Q33835188-CF4A626A-033F-42B8-A92F-47DB49E6FB6BQ34065642-2745C07D-5DB3-437E-8445-2A0AD9BD454CQ34273872-2C14308E-5F93-486A-BAA8-76514A2BC2DAQ34444151-BA991B84-A6A2-4BE6-A314-F24E8C96FAB8Q34527878-C3C7B7A5-DB68-4BC3-909B-6F6F14698D03Q34573907-7AF8A271-CD49-4BF4-B6A6-5FEAB19919C5Q34593874-5CE84B92-5B27-4F0F-A32A-2D362F866E2BQ34717846-7279B8C1-0F89-4AD2-AD49-CD21FF81E2F8Q35038794-C64A165C-74D2-4007-A957-25D0CCAB1FA2Q35204260-6BAFEA47-01FB-489C-9BAF-3DD4FDD3F0ECQ36446900-BFA8F054-82C5-49A5-8B70-133946BA326DQ36567927-3E3EC75E-3C61-44B4-8E18-FF0178BA5533Q37643733-E6CFF6B0-8131-4195-81CC-D38357DAEF1CQ37866631-9007F078-3FF9-4F77-9896-DA0DBFE718B0Q38255634-90D09D1C-30E8-4A3E-B0BF-1B073C523EBEQ38484762-38EDE11E-720A-4816-A202-036F6C8B5F43Q38940488-D2331A74-B539-434B-87CB-ACD3527B688EQ39549251-7D775C3A-FD6E-4E92-B973-58DEB31D5C60Q40130388-DBCB27AB-BFC9-4948-9FC1-466CDD874C6DQ40397362-9EEC756A-51FB-4C47-8A71-1090A2396061Q40537428-AF6DBEA9-2115-4C3B-8825-685AB73BE503Q40588771-9750C836-574F-4E70-9A5E-BA7761EBB4B3Q40637234-CC4DEA95-152E-42E9-8801-6E3FD57A4A78Q40741662-2FD815F9-FFA9-4406-A0C9-790B86130E08Q40778629-C5CABB7B-526E-4797-B307-9B0AC14BD6C9Q41034921-7C37029E-D98F-42B0-9CEC-8FE32CCAD40EQ41499898-3CAC6C69-4226-4724-83E7-5A86FAC3AC66Q42993787-7BC3621C-30DA-4E7A-9BF7-E3E9B7503E45Q42994285-0F043996-6324-4A21-84B5-93F951B716A0Q43000576-B598F803-DC51-46E7-935A-65B0227F5566Q43048872-881AB960-6AD9-4B62-91D8-C6FA6A14A9A5Q43440882-B7BFCDE6-015D-47A1-B443-6F4EE1F51DA2Q45511446-3BBEA78A-F9E4-41FE-AE01-30C38BFCD695Q45572782-33F55A91-A7C0-4104-9488-F42FFC6199AAQ45648838-326CEC14-EF02-4FD4-BC8F-0F49FE19A432
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Peter Liljestrom
@ast
Peter Liljestrom
@en
Peter Liljestrom
@es
Peter Liljestrom
@nl
Peter Liljestrom
@sl
type
label
Peter Liljestrom
@ast
Peter Liljestrom
@en
Peter Liljestrom
@es
Peter Liljestrom
@nl
Peter Liljestrom
@sl
prefLabel
Peter Liljestrom
@ast
Peter Liljestrom
@en
Peter Liljestrom
@es
Peter Liljestrom
@nl
Peter Liljestrom
@sl
P106
P21
P31
P496
0000-0002-2132-0981